16/12/2025
๐๐ข๐ก๐ง๐๐ก๐จ๐๐ก๐ ๐ ๐๐๐๐๐๐ ๐๐๐จ๐๐๐ง๐๐ข๐ก (๐๐ ๐) | ๐ฃ๐ฟ๐ผ๐๐๐ฎ๐๐ฒ ๐๐ฒ๐ฎ๐น๐๐ต ๐๐ป๐ฑ๐ฒ๐
(๐ฃ๐๐) ๐ง๐ฒ๐๐
๐๐ป๐ผ๐๐ถ๐ ๐๐ฎ๐ฏ๐ผ๐ฟ๐ฎ๐๐ผ๐ฟ๐ถ๐ฒ๐, in collaboration with ๐๐ฒ๐ฐ๐ธ๐บ๐ฎ๐ป ๐๐ผ๐๐น๐๐ฒ๐ฟ, conducted a ๐๐ ๐ session on the ๐ฃ๐ฟ๐ผ๐๐๐ฎ๐๐ฒ ๐๐ฒ๐ฎ๐น๐๐ต ๐๐ป๐ฑ๐ฒ๐
(๐ฃ๐๐) test.
We sincerely thank ๐๐ฟ. ๐๐๐บ๐ฎ๐ฟ๐ฎ๐ฝ๐ฝ๐ฎ๐ป ๐๐น๐ฎ๐ด๐ฎ๐ฝ๐ฝ๐ฎ๐ป and the ๐จ๐ฟ๐ผ๐น๐ผ๐ด๐ ๐๐ฒ๐ฎ๐บ, ๐ฃ๐ฒ๐ป๐ฎ๐ป๐ด ๐๐ฒ๐ป๐ฒ๐ฟ๐ฎ๐น ๐๐ผ๐๐ฝ๐ถ๐๐ฎ๐น (๐๐ ๐ฃ๐ฒ๐ป๐ฎ๐ป๐ด) for their active participation and valuable discussion.
๐ ๐๐ ๐ ๐๐ผ๐ฐ๐๐
โข ๐๐ถ๐บ๐ถ๐๐ฎ๐๐ถ๐ผ๐ป๐ ๐ผ๐ณ ๐๐ผ๐๐ฎ๐น ๐ฃ๐ฆ๐ in prostate cancer screening
โข ๐ฃ๐๐ (๐๐ฃ๐ฆ๐, ๐ณ๐ฃ๐ฆ๐ & ๐ฝ๐ฎ๐ฃ๐ฆ๐) โ clinical rationale and interpretation
โข ๐๐บ๐ฝ๐ฟ๐ผ๐๐ฒ๐ฑ ๐ฟ๐ถ๐๐ธ ๐๐๐ฟ๐ฎ๐๐ถ๐ณ๐ถ๐ฐ๐ฎ๐๐ถ๐ผ๐ป for clinically significant prostate cancer
โข ๐ฆ๐๐ฝ๐ฝ๐ผ๐ฟ๐๐ถ๐ป๐ด ๐ฏ๐ถ๐ผ๐ฝ๐๐ ๐ฑ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป-๐บ๐ฎ๐ธ๐ถ๐ป๐ด and patient counselling
๐งช ๐ช๐ต๐ ๐ฃ๐๐?
๐ฃ๐๐ ๐ผ๐ณ๐ณ๐ฒ๐ฟ๐ ๐ต๐ถ๐ด๐ต๐ฒ๐ฟ ๐๐ฝ๐ฒ๐ฐ๐ถ๐ณ๐ถ๐ฐ๐ถ๐๐ for clinically significant prostate cancer compared to PSA alone, helping ๐ฟ๐ฒ๐ฑ๐๐ฐ๐ฒ ๐๐ป๐ป๐ฒ๐ฐ๐ฒ๐๐๐ฎ๐ฟ๐ ๐ฏ๐ถ๐ผ๐ฝ๐๐ถ๐ฒ๐ while maintaining diagnostic confidence.
๐ค ๐๐ ๐ ๐ฏ๐ฟ๐ผ๐๐ด๐ต๐ ๐๐ผ ๐๐ผ๐ ๐ฏ๐ ๐๐ป๐ผ๐๐ถ๐ ๐๐ฎ๐ฏ๐ผ๐ฟ๐ฎ๐๐ผ๐ฟ๐ถ๐ฒ๐ & ๐๐ฒ๐ฐ๐ธ๐บ๐ฎ๐ป ๐๐ผ๐๐น๐๐ฒ๐ฟ
Advancing ๐ฒ๐๐ถ๐ฑ๐ฒ๐ป๐ฐ๐ฒ-๐ฏ๐ฎ๐๐ฒ๐ฑ ๐ฑ๐ถ๐ฎ๐ด๐ป๐ผ๐๐๐ถ๐ฐ๐ through continuous medical education.
Thank you Dr Kumar and team for the meaningful discussion and knowledge exchange.